Harvard Bioscience Inc expected to post a loss of 21 cents a share - Earnings Preview

Harvard Bioscience

07/08/2026 18:10

Harvard Bioscience Inc HBIO.OQ HBIO.O is expected to  show a rise in quarterly revenue when it reports  results on August 11 for the period ending June 30 2026
The Holliston Massachusetts-based  company is expected to report a 4.9% increase in revenue to $21.45 million from $20.45 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on May 12 2026, for the period ended June 30, was for revenue between $20.50 million and $22.50 million.
​LSEG's mean analyst estimate for Harvard Bioscience Inc is for a loss of 21 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Harvard Bioscience Inc is $6.00, about 3.1% below its last closing price of $6.19
The company's guidance on May 12 2026 for the period ended June 30 was for Earnings before Interest, Taxes, Depreciation and Amortization of between USD20.5 million and USD2 million.The company's guidance on May 12 2026 for the period ended June 30 was for gross profit margin between USD57% and USD59%.
This summary was machine generated August 7 at 17:10 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)